Functional dyspepsia is typically treated with serotonin receptor ( 5-HT ) agonists such as Cisapride, Mosapride, Tegaserod and Tandospirone citrate.
However, there are conflicting efficacy data, possibly due to significant heterogeneity between studies.
In a meta-analysis, researchers analyzed the efficacy and safety data from studies evaluating the efficacy of serotonin receptor agonists in patients with functional dyspepsia.
Relevant studies were selected from the Medline, Cochrane, EMBASE, and Google Scholar databases.
The meta-analysis included 10 RCTs ( Randomized Controlled Trials ) which evaluated the efficacy of serotonin receptor agonists in patients with functional dyspepsia ( final total of 892 patients in the serotonin receptor agonist group, and 640 participants in the placebo group ).
The primary outcomes were the response rates and abdominal symptoms score.
The Cochrane Collaboration's tool was used to assess risk.
Sensitivity analysis was carried out using the leave-one-out approach.
Patients treated with serotonin receptor agonists had a significantly higher response rate compared to placebo-treated patients ( pooled odds ratio, OR = 2.99; 95% CI: 1.15-7.77; p = 0.025 ).
Patients treated with serotonin receptor agonists had a significant improvement in symptom scores compared to the placebo group ( pooled standardized mean difference = -0.43; 95% CI: -0.83 to -0.04; p = 0.031 ).
Sensitivity analysis indicated that the pooled estimates for abdominal symptom score might be affected by the Yeoh et al. ( 1997 ) study.
In conclusion, serotonin receptor agonists had a significantly higher efficacy compared to placebo in the treatment of functional dyspepsia. ( Xagena )
Jin M et al, Arch Med Sci 2019; 15 : 23-32